Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 39-44

  Er, Tze Kiong ^a,b   Lin, Sheng Fung ^a   Chang, Jan Gowth ^a,b,c   Hsieh, Li Ling ^a   Lin, Shu Kai ^a   Wang, Li Hsuan ^a   Lin, Chin Wen ^a   Chang, Chao Sung ^a   Liu, Ta Chih ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ARMS; High resolution melting analysis; JAK2 V617F; Mutation; Myeloproliferative disorder

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; GROWTH FACTOR; GUANINE; JANUS KINASE 2; PHENYLALANINE; PROTEIN TYROSINE KINASE; THROMBOPOIETIN; THYMINE; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; ASSAY; CHEMICAL ANALYSIS; CLINICAL ARTICLE; EXON; FEMALE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MALE; METHODOLOGY; MISSENSE MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NUCLEIC ACID BASE SUBSTITUTION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DNA; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 69849094945     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.002     Document Type: Article

References (19)

1. Spano J.P., Milano G., Rixe C., and Fagard R. JAK/STAT signaling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer 42 (2006) 2668-2670
2. Rane S.G., and Reddy E.S. Janus kinases: components of multiple pathways. Oncogene 19 (2000) 5662
3. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 (2005) 22788-22792
4. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
5. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
6. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
7. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365 (2005) 1054-1061
8. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 (2007) 1092-1097
9. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
10. Melzner J., Weniger M.A., Menz C.K., and Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 20 (2006) 157-158
11. McClure R., Mai M., and Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 20 (2006) 168-171
12. Olsen R.J., Tang Z.W., Farkas D.H., Bernard D.W., Zu Y.L., and Chang C.C. Detection of the JAK2V617F mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 130 (2006) 997-1003
13. Tan A.Y., Westerman D.A., and Dobrovic A. A simple, rapid and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol 127 (2007) 977-981
14. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108 (2006) 1865-1867
15. Hammond E., shaw K., Carnley B., Stephanie P., James I., and Hermann R. Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of average copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn 9 (2007) 242-248
16. Kannim S., Thongnoppakhum W., and Auewarakul C.U. Two-round allele specific-polymerase chain reaction: a simple and highly sensitive method for JAK2V617F mutation detection. Clin Chim Acta 401 (2009) 148-151
17. Rapado I., Grande S., Albizua E., et al. High resolution melting analysis for JAK2 exon 14 and exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 11 (2009) 155-161
18. Jones A.V., Cross N.C., White H.E., Green A.R., and Scott L.M. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematological 93 (2008) 1500-1504
19. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7 (2005) 413-421